Managing Partner - The Deerborne Group | Management Consulting | “We help clients identify opportunities, minimize risks, and navigate difficult management challenges."
Illumina has forecasted a 2% to 3% decline in core segment sales for 2024 due to reduced biotech funding impacting R&D investment. Q2 2024 revenue was $1.11 billion, down 5.4% year-over-year but exceeding expectations. Sequencing product sales fell 6.6%, and sequencing instruments dropped 39.9%. Profits were lower than expected, partly due to a $1.47 billion goodwill impairment from the Grail spin-off. Click here to learn more: https://yhoo.it/3AmW6Mw #illumina #genomics #nextgenerationsequencing #venturecapital #privateequity #deerbornedifference
